Trial in 99 adults with newly diagnosed noncavitary MAC lung disease: amikacin liposome inhalation suspension plus azithromycin and ethambutol gave culture conversion by month 6 in 80.6% vs 63.9% with empty liposome control; no drug-related serious adverse events.
RCTn = 99 patients
Daley et al. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial